Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05019092
Other study ID # TVP_UTI_1
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 1, 2021
Est. completion date December 31, 2021

Study information

Verified date August 2021
Source University Of Perugia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: venous thromboembolism (VTE) is a common complication in critically ill patients, admitted to the Intensive Care Units (ICUs). At the present time, there is no validated score to estimate risks and benefits of antithrombotic pharmacological prophylaxis in this subset of patients. Aim of the study: investigating potential harms and benefits of a protocol for systematic screening of DVT in critically ill patients, admitted to an ICU. Expected relevance: systematic screening for deep vein thrombosis (DVT) through ultrasound (US) lower limb veins examination could help defining the indication to antithrombotic pharmacological treatment, but no protocol of systematic screening has been validated so far. Furthermore, the screening could be associated with over-diagnosis and consequent over-treatment, as well as increased management burden for the caregivers and higher healthcare costs.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 100
Est. completion date December 31, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age >18 years old - Admission to the ICU Exclusion Criteria: - duration of stay in ICU <5 days - SARS-CoV-2 infection - established DVT or pulmonary embolism at admission - established coagulation disorder - presence of inferior vena cava filter at the admission - admission/discharge to the ICU of another hospital

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Ultrasound examination of lower limb veins
Ultrasound examination will be performed by trained physicians using a commercially available ultrasound system and 5.0-15.0 MHz linear probe. The examinations consists of a comprehensive B-mode ultrasound protocol, from thigh to ankle, employing compression and color-Doppler at selected sites, according to the Consensus Conference of the Society of Radiologists in Ultrasound.

Locations

Country Name City State
Italy Medicine Interna, Angiologia e Malattie da arteriosclerosi Perugia

Sponsors (1)

Lead Sponsor Collaborator
Ettore Marini

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of deep vein thrombosis Diagnosis of deep vein thrombosis hospitalization in UTI, an average of 10 days
Secondary Progression of deep vein thrombosis (DVT) Extension of a previously diagnosed DVT to a more proximal site hospitalization in UTI, an average of 10 days
Secondary Prophylaxis/ treatment of venous thromboembolism (VTE) Necessity of prophylaxis/ treatment of VTE and its possible modifications during the stay in Intensive Care Unit hospitalization in UTI, an average of 10 days
Secondary Incidence of pulmonary embolism Findings of pulmonary embolism at contrast-enhanced CT scan hospitalization in UTI, an average of 10 days
Secondary Occurrence of major bleeding According to the definition of the International Society of Thrombosis and Hemostasis hospitalization in UTI, an average of 10 days
Secondary Occurrence of anemia Reduction of hemoglobin >2 g/dL without evidence of active bleeding hospitalization in UTI, an average of 10 days
Secondary Duration of ICU stay Duration of ICU stay hospitalization in UTI, an average of 10 days
Secondary Risk of death in ICU Death hospitalization in UTI, an average of 10 days
Secondary Risk of death within 3 months after hospital discharge Death Within 3 months after hospital discharge
Secondary Risk of new hospital admission within 3 months after hospital discharge New hospital admission Within 3 months after hospital discharge
See also
  Status Clinical Trial Phase
Recruiting NCT05003843 - BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis N/A
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Withdrawn NCT04136561 - Novel Strategy to Encourage Early Removal of Central Venous Catheters N/A
Completed NCT03420625 - Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Completed NCT02555111 - Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. Phase 3
Terminated NCT02469376 - Evaluation of a New Imagingtechnologie for Thrombosis Phase 1
Completed NCT01975090 - The SENTRY Clinical Study N/A
Completed NCT02037607 - Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures N/A
Not yet recruiting NCT01357941 - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) N/A
Completed NCT00773448 - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism N/A
Completed NCT00771303 - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed NCT00720915 - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months N/A
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2
Completed NCT00264277 - D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism Phase 4
Completed NCT00365950 - 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE Phase 4
Completed NCT00182403 - Fixed Dose Heparin Study Phase 3
Completed NCT03682419 - Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL) N/A
Not yet recruiting NCT04981327 - The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis Phase 3
Recruiting NCT03240120 - A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism Phase 3